Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1058467 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL8565714 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| Ammonia Solution, Strong SCHEMBL5178346 | 0.97 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL5461417 | 0.77 | TSHR (0.32) | ALDH1A1TSHR | |
| SCHEMBL2378001 | 0.77 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL1965967 | 0.77 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL3630555 | 0.77 | TSHR (0.33) | ALDH1A1TSHR | |
| Hydrogen Peroxide SCHEMBL28392769 | 0.77 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL1965963 | 0.77 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL5468780 | 0.77 | TSHR (0.38) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067644-B2 | Process for conducting an organic reaction in ionic liquids | THE PROCTER & GAMBLE COMPANY (US) | 2011-11-29 | — | — | US | claimed |
| EP-2370387-A2 | PROCESS FOR CONDUCTING AN ORGANIC REACTION IN IONIC LIQUIDS | The Procter & Gamble Company (US) | 2011-10-05 | — | — | EP | claimed |
| US-20110152566-A1 | Process for Conducting an Organic Reaction in Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2011-06-23 | — | — | US | claimed |
| US-12110525-B2 | Method for enzymatic preparation of R-3 aminobutyric acid | Abiochem Biotechnology (Group) Co., Ltd. (CN) | 2024-10-08 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3788040-B1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220090152-A1 | METHOD FOR ENZYMATIC PREPARATION OF R-3 AMINOBUTYRIC ACID | ABIOCHEM BIOTECHNOLOGY CO., LTD. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-11220701-B2 | Method for enzymatic preparation of R-3 aminobutyric acid | ABIOCHEM BIOTECHNOLOGY CO., LTD. (CN) | 2022-01-11 | — | — | US | disclosed |
| EP-3788040-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200232002-A1 | METHOD FOR ENZYMATIC PREPARATION OF R-3 AMINOBUTYRIC ACID | ABIOCHEM BIOTECHNOLOGY CO., LTD. (CN) | 2020-07-23 | — | — | US | disclosed |
| EP-3680340-A1 | METHOD FOR ENZYMATIC PREPARATION OF R-3-AMINOBUTYRIC ACID | Abiochem Biotechnology Co., Ltd. (CN) | 2020-07-15 | — | — | EP | disclosed |
| US-8067644-B2 | Process for conducting an organic reaction in ionic liquids | THE PROCTER & GAMBLE COMPANY (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2370387-A2 | PROCESS FOR CONDUCTING AN ORGANIC REACTION IN IONIC LIQUIDS | The Procter & Gamble Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110152566-A1 | Process for Conducting an Organic Reaction in Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2011-06-23 | — | — | US | disclosed |
| EP-1227111-A1 | TRIPHENYLBORON-CONTAINING POLYMERS AND USE THEREOF | Yoshitomi Fine Chemicals, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| EP-0711147-A1 | SUSPENSIONS FOR DELIVERY OF MEDICAMENT | INSITE VISION INCORPORATED (US) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995003784-A1 | SUSPENSIONS FOR DELIVERY OF MEDICAMENT | INSITE VISION INCORPORATED (US) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152566-A1 | Process for Conducting an Organic Reaction in Ionic Liquids | ACSL3, ACSL1, MCOLN1 | ALDH1A1 142/4885TSHR 3361/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | ALDH1A1 1033/4885TSHR 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.